The emergence of amivantamab represents a significant development for patients battling cancers with c-MET aberration. This unique therapeutic, a targeted blocker of both MET kinase and human epidermal growth factor https://sidneyyqjo062586.wikiexpression.com/6391504/amivantamab_a_potential_solution_for_c_met_associated_growths